ALKS:NASDAQ
Alkermes Plc
$46.71
arrow_upward
+1.39%(+0.64) 1D
$46.71
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 17, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALKS...
Open
$47.10
High
$47.40
Low
$46.41
Mkt. cap
7.84B
Avg. vol.
1.39M
Volume
0.00
P/E ratio
121.37
52-wk high
$55.67
52-wk low
$26.99
EPS
$0.38
Beta
0.27
Shares outstanding
167.76M
No. of employees
2K
Open
$47.10
High
$47.40
Low
$46.41
Mkt. cap
7.84B
Avg. vol.
1.39M
Volume
0.00
P/E ratio
121.37
52-wk high
$55.67
52-wk low
$26.99
EPS
$0.38
Beta
0.27
Shares outstanding
167.76M
No. of employees
2K
News stories
From web sources and news partners
Simply Wall Street
·
8 hours ago
Alkermes (ALKS) Adds A Veteran Director, Is The Stock Still Undervalued?
Profile
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
About Alkermes Plc
CEORichard F. Pops | Richard F. Pops
Employees2.05K
Founded1987
Headquarters-
SectorBiotechnology
Websitealkermes.com